Home / Health / New Hope for PPD: Oral Treatment Completes Phase III
New Hope for PPD: Oral Treatment Completes Phase III
21 Jan
Summary
- Lipocine's oral brexanolone trial for PPD finished enrollment and dosing.
- The Phase III study showed no serious adverse events or loss of consciousness.
- Data will support a 2026 new drug application submission for at-home treatment.
Lipocine has announced the successful completion of enrollment and participant dosing in its Phase III clinical trial for LPCN 1154, an oral formulation of brexanolone designed to treat postpartum depression (PPD).
The double-blind, randomized study involved 90 women aged 15 and above diagnosed with severe PPD. Conducted entirely in an outpatient setting, the trial received positive feedback from the U.S. Food and Drug Administration (FDA).
LPCN 1154 has shown a favorable safety profile, with no observed cases of excessive sedation, discontinuation, serious adverse events, or loss of consciousness among participants. Crucially, its administration does not require medical monitoring by a healthcare provider.
Data from this trial is anticipated to support a 505(b)(2) new drug application submission in 2026. The company aims to provide rapid relief from PPD with a convenient at-home treatment option, particularly beneficial for those at higher risk of suicide.
Lipocine anticipates reporting topline safety and efficacy results in early Q2 2026. The company's broader pipeline addresses various conditions including major depressive disorder, epilepsy, and obesity management.
